Ovarian neoplasm
Therapeutic area
Reproductive Health
Rare disease
No
- Definition
- A benign, borderline, or malignant neoplasm involving the ovary.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Ovarian neoplasm
- Therapeutic area
- Reproductive Health
- ovarian neoplasm
- neoplasm of ovary
- neoplasm of the ovary
- ovarian neoplasm
- ovarian tumor
- ovarian tumors
- ovarian tumour
- ovarian tumours
- ovary neoplasm
- ovary neoplasm (disease)
- ovary tumor
- ovary tumour
- tumor of ovary
- tumor of the ovary
- tumour of ovary
- tumour of the ovary
- Severity
- Severe
- Endocrinology
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0021068
- Parent condition
- MONDO:0005558
Related records
Broader conditions (14)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine system disorder
- Female reproductive system disorder
- Female reproductive system neoplasm
- Gonadal disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Ovarian disorder
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (142)
- Atypical Meigs syndrome
- Benign ovarian mucinous tumor
- Benign ovarian sex cord-stromal tumor
- Benign struma ovarii
- Borderline epithelial tumor of ovary
- Borderline ovarian serous tumor
- Childhood choriocarcinoma of the ovary
- Childhood immature teratoma of ovary
- Childhood mature teratoma of the ovary
- Childhood ovarian embryonal carcinoma
- Childhood ovarian yolk sac tumor
- Childhood teratoma of the ovary
- Choriocarcinoma of ovary
- Dermoid cyst of ovary
- Dysgerminoma of ovary
- Familial ovarian cancer
- Familial ovarian carcinoma
- Gestational ovarian choriocarcinoma
- Hereditary site-specific ovarian cancer syndrome
- Hypercalcemic type ovarian small cell carcinoma
Trials (3,234)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- (GI-RADS) in Preoperative Evaluation of Adnexal Masses
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
- 11C Topotecan PET Imaging
- 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
- 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
- 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 3D Prediction of Patient-Specific Response
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
- 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
Approved drugs (11)
- Bevacizumab
- Carboplatin
- Doxorubicin hydrochloride
- Igovomab
- Melphalan hydrochloride
- Niraparib tosylate monohydrate
- Olaparib
- Paclitaxel
- Rucaparib camsylate
- Topotecan hydrochloride
- Trabectedin
Drugs in development (53)
- 9-aminocamptothecin Phase 2
- Adebrelimab Phase 2
- Aflibercept Phase 2
- Aldesleukin Phase 2
- Alectinib Phase 2
- Anetumab ravtansine Phase 1
- Aspirin Phase 2
- Atezolizumab Phase 3
- Batiraxcept Phase 3
- Berzosertib Phase 2
- Canfosfamide hydrochloride Phase 3
- Cediranib Phase 3
- Celecoxib Phase 2
- Cisplatin Phase 3
- Cyclophosphamide Phase 3
- Dexamethasone Phase 3
- Docetaxel Phase 3
- Dostarlimab Phase 3
- Doxorubicin Phase 3
- Erlotinib Phase 2
Other linked drugs (3)
- Ifosfamide
- Melphalan
- Mirvetuximab soravtansine